SCHEMBL30298622

SCHEMBL30298622

COc1ccc(N=C=S)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.44
APLNR P35414 1/20 0.41
NNMT P40261 1/20 0.40
KDM4E B2RXH2 1/20 0.38
P2RY6 Q15077 1/20 0.38
CYP2A6 P11509 2/20 0.38
MIF P14174 1/20 0.38
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
GRM5 P41594 1/20 0.36
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21020 1.00 MPI (0.44) MPIAPLNRNNMTKDM4EP2RY6
Hydrochloric Acid SCHEMBL10418405 0.98 MPI (0.43) MPIAPLNRNNMTKDM4EP2RY6
SCHEMBL11710048 0.85 RAB9A (0.42) APLNRKDM4EMIFMEN1KMT2A
SCHEMBL11710623 0.84 MAPT (0.45) APLNRP2RY6MIFMEN1KMT2A
SCHEMBL856393 0.81 MPI (0.44) MPINNMTKDM4ECYP2A6MKNK1
SCHEMBL11712035 0.81 MIF (0.46) APLNRMIFMEN1KMT2A
SCHEMBL11709850 0.81 NPC1 (0.52) KDM4EP2RY6MIFMEN1KMT2A
SCHEMBL11709823 0.81 ALDH1A1 (0.42) P2RY6MIF
SCHEMBL11707937 0.79 MEN1 (0.58) APLNRKDM4EMEN1KMT2A
SCHEMBL11707857 0.78 KDM4E (0.51) KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MPI 3758/4885APLNR 3496/4885NNMT 2677/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MPI 3758/4885APLNR 3496/4885NNMT 2677/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG MPI 3758/4885APLNR 3496/4885NNMT 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.